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Abstract—A series of -amino--sulphone hydroxamates was prepared and evaluated for potency versus 
MMP-13 and selectivity versus MMP-1.  Various substituents were employed on the -amino group (P1 
position), as well as different groups attached to the sulphone group extending into P1’.  Low nanomolar 
potency was obtained for MMP-13 with selectivity versus MMP-1 of >1000X for a number of analogues. 
 
Matrix metalloproteinase (MMP) enzymes1,2 are endopeptidases that mediate the breakdown of structural 
proteins of the extracellular matrix and are involved in many normal physiological processes such as the 
remodeling of connective tissues and basement membranes.3 The activity of these enzymes is closely 
controlled through expression as a latent proform that requires prior activation for activity, and also through 
direct inhibition by tissue inhibitors of metalloproteinases (TIMPs). Elevated levels of MMPs are associated 
with certain pathologies including osteoarthritis (OA) and rheumatoid arthritis (RA).  Recently, Freemont et. 
al.4 reported the use of in situ zymography to localize type II collagen degrading activity in osteoarthritic 
human articular cartilage, and in situ hybridization to localize MMP-13 mRNA.  Significantly, they found that 
MMP-13 mRNA expression co-distributed with type II collagenase activity in articular chondrocytes, and that 
MMP-13 was upregulated in articular osteoarthritic cartilage but not in cartilage from normals.  Thus 
inhibition of the relevant collagenase enzymes, particularly MMP-13, may prove to be clinically effective in 
halting the advance of OA and RA.5  Roche collagenase inhibitor Ro 32-35556 inhibits collagenases 1, 2 and 3 
(MMP-1, MMP-8, and MMP-13, respectively) and prevents cartilage breakdown both in vitro and in vivo.  For 
the treatment of arthritis we targeted inhibitors of MMP-13 that spare interstitial collagenase (MMP-1) in order 
to avoid the musculoskeletal side effect observed clinically with the broad-spectrum inhibitor marimastat.7  
The hypothesis8 that sparing MMP-1 will eliminate the fibroplasia seen with broad-spectrum inhibitors is still 
speculative.  We wish to report preliminary SAR of a series of potent -amino--sulphone9,10 hydroxamate 
MMP-13 inhibitors that are selective in sparing MMP-1. 
 
Racemic -amino compounds bearing methoxyphenyl sulphones and phenoxyphenyl sulphone moieties were 
prepared as shown in Scheme 1. The Michael acceptor methyl-2-acetamidoacrylate (1) was reacted with 4-
methoxythiophenol (XR1 = OMe) or 4-phenoxythiophenol, which was prepared via Newmann rearrangement11 
from 4-phenoxyphenol as we reported previously for our -sulphone thiol series of MMP inhibitors.12  Oxone 
treatment of the crude thioether afforded the sulphone 2 in excellent yield from the acrylate.  Vigorous 
hydrolysis of 2 with concentrated hydrochloric acid in glacial acetic acid afforded the free amino acid which 
was re-esterified with thionyl chloride in methanol.  Derivitization with the appropriate R2 reagent and direct 
conversion of the methyl ester to the hydroxamate with aqueous hydroxylamine in methanol/tetrahydrofuran 
afforded the hydroxamic acid 3. 
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Scheme 1 
Racemic compounds bearing the phenylthiophenyl sulphone moiety were prepared as illustrated in Scheme 2.  
4-Fluorothiophenol was added in a conjugate fashion to methyl-2-acetamidoacrylate (1), and treatment of the 
crude thioether with Oxone gave the sulphone 4.  Controlled hydrolysis of the methyl ester gave the 
carboxylic acid with the acetamide intact.  Nucleophilic aromatic displacement of the fluoride proceeded 
cleanly on the carboxylate salt to afford 5, whereas attempts to perform the fluoride displacement directly on 
ester 4 did not afford the desired product due to competing beta-elimination.  Hydrolysis of the acetamide 5 
followed by derivitization with the appropriate R2 reagent gave carboxylic acid 6.  The hydroxamic acid 7 was 
then prepared by employing the standard EDC/HOBT coupling with tetrahydropyranyl hydroxylamine 
followed by deprotection under acidic conditions. 
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Scheme 2 
Chiral (R)--amino--phenylthiophenyl sulphones were synthesized from N-BOC-L-serine--lactone which 
was prepared from BOC-L-serine by the procedure of Vederas13 (Scheme 3).  Nucleophilic ring-opening of 8 
with sodium 4-fluorothiophenoxide gave the sulfide, which was oxidized directly with Oxone to afford 9 with 
(R)-stereochemistry.  Nucleophilic aromatic displacement of the aryl fluoride with thiophenol followed by 
acidic deprotection of the BOC group and acylation afforded the functionalized carboxylic acid, which was 
converted to hydroxamate 10 via coupling with THPONH2 and deprotection. 
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Scheme 3 
Chiral -amino -phenoxyphenyl sulphones were prepared by sodium thiolate displacement14 of  the  
tosylate15 of Cbz-L-serine methyl ester (11) to afford 12 after oxidation with Oxone.  Hydrogenolysis, 
acylation and conversion of the methyl ester of  12 to the hydroxamate with hydroxylamine afforded 
compounds of type 13 with (R)-stereochemistry (Scheme 4).  It may be noted that Schemes 3 and 4 are 
complementary with respect to amine protecting groups and also with respect to the state of the carboxylate.  
Specifically, the nucleophilic aromatic fluoride displacement accomplished on free carboxylic acid 9 was not 
viable on the corresponding Cbz-protected methyl ester prepared by the general method of Scheme 4 due to 
beta-elimination. 
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Scheme 4 
Chiral (R)--amino -phenoxyphenyl sulphones were prepared with minor modifications of the above 
procedures according to Scheme 5.  Commercially available (S)-BOC-N-methyl-serine (14) was esterified with 
methyl iodide, then treated with 4-phenoxythiophenol under Mitsunobu conditions.  Oxidation of the resulting 
sulfide with tetra-N-butylammonium Oxone gave sulphone 15.  Removal of the tert-butylcarbamate 
protecting group under acidic conditions was followed by functionalization with the appropriate R2 reagent.  
The methyl ester was converted directly to the hydroxamate 16 by treating with aqueous hydroxylamine, albeit 
in lower yields as expected, due to the increased steric hindrance in the -position of the ester. 
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Scheme 5 
We elected to initially to examine racemic -amino--sulphones in order to explore potency for MMP-13 and 
selectivity versus MMP-1 (Table 1).  A 4-methoxyphenyl sulphone moiety in P1’ (XR2 = OMe) afforded lower 
potency and selectivity16–18 with the notable exception of compound 20 bearing a Cbz-glycine moiety in the P1 
position appended to the -amino group.  The Cbz-glycine group was selected to probe for an additional 
binding region to enhance potency.  Incorporation of the phenylthiophenyl moiety (XR2 = SPh) afforded an 
modest increase in potency (17 vs 21) and very high levels of selectivity (compounds 21–25).  The Cbz-
glycine moiety again afforded a large jump in potency for MMP-13, which translated to exceptional selectivity 
(>12,000X) versus MMP-1.  Utilization of the diaryl ether in P1´ (XR1 = OPh, 26–28) led to compounds of 
excellent potency for MMP-13 but which had somewhat lower selectivity than the phenylthiophenyl 
compounds versus MMP-1. 
Table 1  IC50 (nM)19 values for racemic -amino--sulphone hydroxamates 
NH
S
R2
O O
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N
H
O
HO
 
Compound XR1 R2 MMP-13 MMP-1 MMP-1/13 
17 OMe Ac 15 300 20 
18 OMe BOC 15 1500 100 
19 OMe H 15 250 17 
20 OMe CbzGly <1.0 40 >40 
21 SPh Ac 5.9 >10,000 >1700 
22 SPh Cbz 3.7 >10,000 >2700 
23 SPh Tos 0.4 600 1500 
24 SPh H 24 >10,000 420 
25 SPh CbzGly 0.8 >10,000 >12,000 
26 OPh Ac 1.1 770 700 
27 OPh Cbz 1.1 1400 1300 
28 OPh Tos 0.6 400 670 
 
Table 2 shows the enzyme results of chiral (R)--amino--sulphones derived from L-serine.  Direct 
comparison of the single enantiomers and racemates of N-acetyl (30 vs 21) and N-Cbz (31 vs 22) showed an 
increase in potency expected for the eutomers, and an accompanying (apparent) increase in selectivity.  
Comparison of BOC derivatives 29 and 32 reveal again the order of magnitude increase in potency of the 
diphenyl ether versus the diaryl thioether (X = O vs X = S), although the thioethers are more selective.  
Hydrophilic groups including isonicotinyl (compound 33) were incorporated into R2 to increase water 
solubility, and the unsubstituted analog 34 (R2 and R3 = H) was also prepared.  Bulky groups (such as 
dimethoxybenzoyl in compound 34) were introduced to increase the half-life of these compounds by adding 
steric hindrance to block the metabolism of the hydroxamate moiety.  This was the reason for preparation of 
the disubstituted compounds 36–39 (R3 = CH3).  These compounds exhibited sub-nanomolar potency for 
MMP-13 and good selectivity versus MMP-1.  The acetyl analog 36 showed unexpected potency versus MMP-
1. 
Table 2  IC50 (nM)19 values for (R)--amino--sulphone hydroxamates 
N
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Compound X R2 R3 MMP-13 MMP-1 MMP-1/13 
29 S BOC H 4.0 >10,000 >2500 
30 S Ac H 2.9 10,000 3400 
31 S Cbz H 0.4 8,000 20,000 
32 O BOC H 0.3 500 1600 
33 O isonicotinyl H 0.8 900 1100 
34 O 2,6-dimethoxybenzoyl H 0.4 350 870 
35 O H CH3 0.4 440 1100 
36 O Ac CH3 0.2 90 450 
37 O BOC CH3 0.3 1600 5300 
38 O 4-pyridineacetyl CH3 2.0 258 130 
39 O benzyl CH3 0.2 475 2400 
 
Selected analogs were dosed orally in rats at 20 mpk to assess absorption by measuring Cmax, and the 
concentration remaining at 6 h was used as an initial rough indicator of the half-life.   N-Methyl derivative 35 
showed a high Cmax of 6.66 ug/mL, with 0.049 ug/mL remaining at 6 h, and acetyl analogue 36 exhibited a 
Cmax of 2.45 ug/mL (0.060 ug/mL at 6 h).  Pyridineacetyl analog 38 had a somewhat lower Cmax of 0.71 ug/mL, 
but was not detected at 6 h.  These analogs exhibited higher Cmax values than compounds 32, 33, and 34, which 
exhibited Cmax values of <0.2 ug/mL. 
 
 
In summary, we have described a promising series of -amino--sulphone hydroxamates that are potent 
inhibitors of MMP-13 that spare MMP-1.  Potency and selectivity were modulated by varying the P1’ moiety 
(XR1), and a wide variety of substituents are tolerated in the P1 (solvent exposed) -amino position of MMP-
13. This position was utilized to modulate solubility and pharmacokinetic parameters.  Compounds 35 and 36 
showed good absorption when administered orally in the rat.  The activity of these MMP-1 sparing -sulphone 
hydroxamates in animal models of arthritis and cancer will be disclosed in due course. 
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